Rentschler Biopharma, a global leader in contract development and manufacturing of biopharmaceuticals, has teamed up with VarmX, a biotech company working on new treatments for blood clotting issues. They are collaborating to produce VarmX’s main program, VMX-C001, for Phase 3 clinical trials and eventual commercialization. VMX-C001 is a treatment designed to help patients who are bleeding heavily or need urgent surgery while taking certain blood thinners known as FXa DOACs.
Rentschler Biopharma began supporting the early stages of VMX-C001’s development in 2022 at its site in Laupheim, Germany. Now, VarmX is using GMP (Good Manufacturing Practice) material from Rentschler Biopharma to move forward with Phase 3 trials. All future Phase 3 clinical supplies, including process validation, will be produced at Rentschler Biopharma’s Milford, MA site. This will help transition smoothly into late-stage clinical trials and commercial production.
VMX-C001 is a modified protein designed to bypass the blood-thinning effects of FXa DOACs and help restore normal blood clotting. It has received Fast Track Designation from the FDA and was also given a Phase 1 waiver by Japan’s PMDA. VarmX has also partnered with CSL in a global collaboration. The global Phase 3 trial, named EquilibriX-S, will begin in early 2026, focusing on urgent surgeries.
According to coherent market insights, the Biotechnology Market is expected to grow at a CAGR of 12.3% during 2025 to 2032. Currently, the market is at USD 1,034.63 Bn in 2025 and is expected to be around USD 2,330.47 Bn by 2032. Increasing prevalence of chronic diseases, new product launches, and strategies like mergers, acquisitions, and collaboration are expected to drive the global biotechnology market growth over the forecast period.
“Launching e.l.f. at ULTA Beauty in Mexico is a milestone moment for both companies,” said Jennie Laar, Senior Vice President and Chief Commercial Officer, e.l.f. Beauty. “e.l.f. and ULTA are kindred spirits in our shared mission to make beauty accessible to all through the lenses of affordability and availability. We’re thrilled to join forces in a market with incredible opportunity, bringing premium-quality products to our community at exceptional value.”
John Glasspool, Chief Executive Officer of VarmX, said: “Manufacturing readiness is key as we prepare to commence our landmark global EquilibriX-S Phase 3 trial, evaluating the ability of VMX-C001 to rapidly restore coagulation in patients taking any FXa DOAC undergoing urgent surgery. We’re pleased to extend our partnership with Rentschler Biopharma as we drive VMX-C001 towards becoming a new treatment option for the substantial number of patients on FXa DOACs who need emergency surgery.”
Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma, commented: “We are honored to continue our collaboration with VarmX, which reflects exactly what Rentschler Biopharma stands for: high‑impact technical expertise, long‑term partnership grounded in trust, and tailored solutions that bring breakthrough therapies to patients. As VMX‑C001 advances toward Phase 3, we remain fully committed to delivering seamless continuity, leveraging our FDA‑licensed sites in the EU and the U.S. and deep experience in late‑stage development and market approval. Guided by our vision of advancing medicine to save lives – together, we look forward to supporting VarmX on the path to commercialization.”
Source:
Press Release: Rentschler Biopharma
Company: Rentschler Biopharma
